样式: 排序: IF: - GO 导出 标记为已读
-
Overcoming the real and imagined barriers to cholesterol screening in pediatrics J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-03-06 Tyler J. Schubert BA, Samuel S. Gidding MD, Laney K. Jones PharmD MPH
-
Malar rash and hand tremor in early symptoms of cerebrotendinous xanthomatosis and the effect of chenodeoxycholic acid on them J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-02-28 Banu Kadıoğlu Yılmaz MD, Halil Çelik MD
Cerebrotendinous xanthomatosis (CTX, OMIM #213700) is a rare but treatable lipid storage disease resulting from mutations in the CYP27A1 gene. The study aims to evaluate patients diagnosed with CTX and reveal new information, especially about the signs of CTX and patients' response to the treatment. The study was conducted retrospectively in 12 definitively diagnosed CTX patients. The patients' clinical
-
Pancreatitis polygenic risk score is associated with acute pancreatitis in multifactorial chylomicronemia syndrome J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-02-23 Simon-Pierre Guay, Martine Paquette, Amélie Taschereau, Véronique Desgagné, Luigi Bouchard, Sophie Bernard, Alexis Baass
Multifactorial chylomicronemia syndrome (MCS) is a severe form of hypertriglyceridemia associated with an increased risk of acute pancreatitis (AP). The risk of AP is heterogenous and is associated with increased level of triglycerides (TG) and presence of rare variants in TG metabolism-related genes. To determine if the accumulation of common variants in pancreatitis susceptibility genes, measured
-
Statins Use for Primary Prevention of Cardiovascular Disease: A Population-based Digitally Enabled Real-world Evidence Cross-Sectional Study in Primary Care in Brazil J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-02-20 Karla Santo, Raul D. Santos, Alysson Nathan Girotto, Josue Nieri, Frederico Monfardini, Priscila Raupp, Pedro Marton Pereira, Otavio Berwanger, M. Julia Machline-Carrion
-
Lipoprotein(a) testing in lipid clinics across the UK: Results of a national survey J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-02-15 Saleem Ansari, R. Dermot G. Neely, Jules Payne, Jaimini Cegla
Lipoprotein(a) is an independent risk factor for cardiovascular disease and its use is recommended in national and international guidelines for cardiovascular disease risk stratification. We undertook a survey to understand the availability and application of lipoprotein(a) measurement across UK lipid clinics. Fifty-three out of an estimated 200 lipid clinics (27%) provided responses. 81% of fifty-three
-
Association of Lipoprotein (a) with peri-coronary inflammation in persons with and without HIV infection J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-02-15 Erin Zisman, Mian Hossain, Nicholas T. Funderburg, Robert Christenson, Jean Jeudy, Shana Burrowes, Allison G. Hays, Nivya George, Michael L. Freeman, Heather Rebuck, Sarah E. Mitchell, Michael Miller, Shashwatee Bagchi
Persons with HIV (PWH) have an increased risk of developing cardiovascular disease (CVD) compared to persons without HIV (PWoH). Lipoprotein a (Lp(a)) is a known atherosclerotic risk factor in PWoH, but there are no studies investigating Lp(a) and peri-coronary inflammation. To investigate whether Lp(a) is associated with peri-coronary inflammation as assessed by the fat attenuation index (FAI) and
-
Use of lipid ratios to predict vascular target organ damage in youth J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-02-10 Sarah E. Henson M.D, Elaine M. Urbina M.D.M.S
Elevated lipid levels are risk factors for early atherosclerosis. Lipid ratios have emerged as potentially stronger predictors of adverse cardiovascular changes and atherogenic cholesterol. Risk stratification in youth with obesity or type 2 diabetes may be improved by using lipid ratios. We sought to determine if lipid ratios would identify abnormalities in arterial structure and stiffness in adolescents
-
Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-02-08 Raman Puri, Manish Bansal, Vimal Mehta, P. Barton Duell, Nathan D. Wong, S.S. Iyengar, Dinesh Kalra, Devaki R. Nair, Navin C. Nanda, Jagat Narula, P. Deedwania, Jamal Yusuf, Jamshed J. Dalal, Sadanand Shetty, Vinod M. Vijan, Rajeev Agarwala, Soumitra Kumar, Kris Vijay, Aziz Khan, Gurpreet Singh Wander, P.C. Manoria, S.K. Wangnoo, Viswanathan Mohan, Shashank R. Joshi, Balbir Singh, Prafulla Kerkar,
: In 2016, the Lipid Association of India (LAI) developed a cardiovascular risk assessment algorithm and defined low-density lipoprotein cholesterol (LDL-C) goals for prevention of atherosclerotic cardiovascular disease (ASCVD) in Indians. The recent refinements in the role of various risk factors and subclinical atherosclerosis in prediction of ASCVD risk necessitated updating the risk algorithm and
-
Association of cardiometabolic and vascular atherosclerosis phenotypes on non-contrast chest CT with incident heart failure in patients with severe hypercholesterolemia J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-02-07 Pamela Piña, Daniel Lorenzatti, Francesco Castagna, Jeremy Miles, Toshiki Kuno, Andrea Scotti, Javier Arce, Ari Feinberg, Dou Huang, Jake Gilman, Ephraim Leiderman, Jonathan Daich, Paul Ippolito, Carlos A. Gongora, Aldo L. Schenone, Lili Zhang, Carlos J. Rodriguez, Michael J. Blaha, Damini Dey, Daniel S. Berman, Salim S. Virani, Jeffrey M. Levsky, Mario J. Garcia, Leandro Slipczuk
Association of cardiometabolic and atherosclerotic markers on non-contrast Chest CT with Heart Failure Hospitalization in Patients with Severe Hypercholesterolemia. * Unadjusted Hazard Ratio for the moderate-to-severe category. ASCVD: atherosclerotic cardiovascular disease, CAC: coronary artery calcification. HF: heart failure, LDL-C: low-density lipoprotein cholesterol, NAFLD: non-alcoholic fatty
-
High density lipoprotein infusion therapy: A review J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-02-07 H. Bryan Brewer, Ernst J. Schaefer, Borek Foldyna, Brian B. Ghoshhajra
Increased cholesterol-rich, low-density, non-calcified atheromas as assessed by computer coronary tomography angiography (CCTA) analyses have been shown to predict myocardial infarction significantly better than coronary artery calcium score or the presence of obstructive coronary artery disease (CAD) as evaluated with standard coronary angiography. Low serum high-density lipoprotein (HDL) cholesterol
-
Sex differences in the associations of HDL particle concentration and cholesterol efflux capacity with incident coronary artery disease in type 1 diabetes: The RETRO HDLc cohort study J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-01-29 Tina Costacou, Rachel G. Miller, Karin E. Bornfeldt, Jay W. Heinecke, Trevor J. Orchard, Tomas Vaisar
Background In type 1 diabetes, women lose their relative protection (compared to men) against coronary artery disease (CAD), while HDL-C is less strongly associated with lower CAD risk in women. Objective We aimed to assess whether sex differences in the HDL particle concentration (HDL-P) and cholesterol efflux capacity (CEC) association with CAD may explain these findings. Methods HDL-P (calibrated
-
Obesity and atherosclerotic cardiovascular disease in adults with heterozygous familial hypercholesterolemia: an analysis from HELLAS-FH registry J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-01-24 Fotios Barkas, Christos V. Rizos, George Liamis, Ioannis Skoumas, Anastasia Garoufi, Loukianos Rallidis, Genovefa Kolovou, Konstantinos Tziomalos, Emmanouil Skalidis, George Sfikas, Vasilios Kotsis, Michalis Doumas, Panagiotis Anagnostis, Vaia Lambadiari, Georgia Anastasiou, Iosif Koutagiar, Achilleas Attilakos, Estela Kiouri, Vana Kolovou, Georgios Polychronopoulos, Evangelos Liberopoulos
-
Sex Differences in the Presentation, Treatment and Outcomes of Patients with Homozygous Familial Hypercholesterolemia J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-01-14 Zobaida Al-Baldawi, Leslie Brown, Isabelle Ruel, Alexis Baass, Jean Bergeron, Lubomira Cermakova, Patrick Couture, Daniel Gaudet, Gordon A. Francis, Robert A. Hegele, Iulia Iatan, G.B. John Mancini, Brian W McCrindle, Thomas Ransom, Mark H. Sherman, Ruth McPherson, Jacques Genest, Liam R. Brunham
-
Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-01-11 P. Barton Duell, Maciej Banach, Alberico L. Catapano, Ulrich Laufs, G.B. John Mancini, Kausik K. Ray, Christine Broestl, Yang Zhang, Lei Lei, Anne C. Goldberg
-
Comprehensive assessment of the combined impact of dyslipidemia and inflammation on chronic kidney disease development: A prospective cohort study J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-01-10 Jihyun Yoon, Taehwa Han, , Yu-Jin Kwon
Background : There remains a limited comprehensive understanding of how dyslipidemia and chronic inflammation collectively contribute to the development of CKD. Objective : We aimed to identify clusters of individuals with five variables, including lipid profiles and C-reactive protein (CRP) levels, and to assess whether the clusters were associated with incident CKD risk. Methods : We used the Korean
-
Using Implementation Science to Develop a Familial Hypercholesterolemia Screening Program in Primary Care: the CARE-FH Study J. Clin. Lipidol. (IF 4.4) Pub Date : 2024-01-04 Laney K. Jones, Katrina M. Romagnoli, Tyler J. Schubert, Katarina Clegg, H. Lester Kirchner, Yirui Hu, Dylan Cawley, Victoria Norelli, Marc S. Williams, Samuel S. Gidding, Alanna K. Rahm
-
Association of Cumulative Low-density Lipoprotein Cholesterol Exposure with Vascular Function J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-12-25 Takayuki Yamaji, Farina Mohamad Yusoff, Shinji Kishimoto, Masato Kajikawa, Kenichi Yoshimura, Yukiko Nakano, Chikara Goto, Takahiro Harada, Aya Mizobuchi, Shunsuke Tanigawa, Tatsuya Maruhashi, Yukihito Higashi
-
Modern approaches to the management of homozygous familial hypercholesterolemia in the Middle East and North Africa J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-12-15 Dr Abdullah Al-Ashwal, Dr Mohammed Al Dubayee, Dr Afaf Alsagheir, Dr Mutaz Al-Sabah, Dr Ahmed Al-Sarraf, Dr Zuhier Awan, Dr Tawfeg Ben-Omran, Dr Saif Al-Yaarubi, Dr Angham Almutair, Dr Abdelhadi Habeb, Dr Faouzi Maatouk, Manal Alshareef, Dr Naji Kholaif, Prof Dirk Blom
Homozygous familial hypercholesterolaemia (HoFH) is a severe form of FH in which inheritance of two defective or null mutations in genes associated with metabolism of low-density lipoprotein cholesterol (LDL-C) results in extremely high LDL-C, premature atherosclerotic cardiovascular disease (ASCVD) and mortality. Treatment of HoFH comprises a multi-modal approach of statins, ezetimibe, lipoprotein
-
JCL Roundtable: Evolution of Preventive Cardiology and Clinical Lipidology J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-12-15 Martha Gulati, Erin D. Michos, William E. Boden, John R. Guyton
It's a privilege to discuss preventive cardiology with 3 of the foremost U.S. leaders in this growing subspecialty. Preventive cardiology is the practice of primordial, primary, and secondary prevention of cardiovascular disease. It employs an integrated team of clinicians committed to preventing all forms of cardiovascular disease, including ischemic heart disease, heart failure, atrial fibrillation
-
No benefit of vitamin D supplementation on muscle function and Health-Related Quality of Life in primary cardiovascular prevention patients with statin-associated muscle symptoms: a randomized controlled trial J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-12-15 Paul Peyrel, Pascale Mauriège, Jérôme Frenette, Nathalie Laflamme, Karine Greffard, Sébastien S. Dufresne, Claire Huth, Jean Bergeron, Denis R. Joanisse
Background Statins are the leading lipid-lowering drugs, reducing blood cholesterol by controlling its synthesis. Side effects are linked to the use of statins, in particular statin-associated muscle symptoms (SAMS). Some data suggest that vitamin D supplementation could reduce SAMS. Objective The purpose of this study was to evaluate the potential benefits of the vitamin D supplement in a randomized
-
Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3 J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-12-10 Andre Zimerman, Stephen D. Wiviott, Jeong-Gun Park, Sabina A. Murphy, Xinhui Ran, Candace R. Bramson, Madelyn Curto, Vesper Ramos, Alexandra Jevne, Julia F. Kuder, Subodh Verma, Wojtek Wojakowski, Steven G. Terra, Marc S. Sabatine, Brian A. Bergmark, Nicholas A. Marston
BACKGROUND Angiopoietin-like 3 protein (ANGPTL3) is a novel therapeutic target for hyperlipidemia. Vupanorsen, an antisense oligonucleotide targeting ANGPTL3, reduced triglycerides up to 57%, but caused dose-dependent increases in hepatic fat fraction (HFF). OBJECTIVE To determine the degree of HFF progression with escalating doses of vupanorsen, the correlation between changes in HFF and liver enzymes
-
Universal Lipid Screening in Adolescents to Identify Familial Hypercholesterolemia in a Large Healthcare System J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-12-08 Alan B Cortez, Miriam Salvador, Qiaowu Li, Audrey Briscoe
-
-
-
From the Editors: New concepts in obesity and cardiovascular disease J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-12-09 P. Barton Duell, Kevin C. Maki
Abstract not available
-
-
A Case Report Of Tangier Disease Presents With Acute Sensorimotor Polyneuropathy And Its Treatment Approach J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-12-02 Saniye Karabudak, Vildan Güzel, Beril Güler, Bülent Uyanık, Azize Esra Gürsoy
Polyneuropathy is a frequently encountered clinical presentation where peripheral nerves are affected due to the same cause and physiopathological processes. We report a case of acute sensorimotor polyneuropathy in a patient with Tangier disease (TD) who was treated with miglustat which is a glycosphingolipid synthesis inhibitor. TD is a very rare genetic disorder caused by mutations in the ABCA1 gene
-
-
Habitual fish oil supplementation, genetic susceptibility of kidney stones and the risk of new-onset kidney stones J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-27 Xiaoqin Gan, Mengyi Liu, Panpan He, Ziliang Ye, Hao Xiang, Chun Zhou, Sisi Yang, Yanjun Zhang, Yuanyuan Zhang, Yu Huang, Xianhui Qin
Objective We aimed to assess the association between habitual fish oil use and new-onset kidney stones in participants with different levels of genetic risks of kidney stones. Methods 477,311 participants free of kidney stones at baseline from the UK Biobank cohort were included. Fish oil use was collected by both food frequency questionnaires and 24-h dietary recalls. A genetic risk score (GRS) for
-
Fatty acid analysis in serum of patients with elevated lipoprotein(a) and cardiovascular disease undergoing lipoprotein apheresis J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-28 Agnieszka Mickiewicz, Joanna Marlęga-Linert, Monika Czapiewska, Marta Marcinkowska, Aleksandra Krzesińska, Agnieszka Kuchta, Marcin Fijałkowski, Marcin Gruchała, Adriana Mika
-
-
-
From the Editors: More Hot Topics in Clinical Lipidology J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-28 Kevin C. Maki, P. Barton Duell
Abstract not available
-
Lipoprotein(a) levels and carotid intima-media thickness in children: A 20-year follow-up study J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-27 L.M. de Boer, B.A. Hutten, S. Tsimikas, C. Yeang, A.H. Zwinderman, J. Kroon, A. Revers, J.J.P. Kastelein, A. Wiegman
Elevated lipoprotein(a) [Lp(a)] is independently associated with cardiovascular disease (CVD). In a recent long-term follow-up study involving children with familial hypercholesterolemia, Lp(a) levels contributed significantly to early atherosclerosis, as measured by carotid intima-media thickness (cIMT). To determine if this holds true for children without FH, we conducted a 20-year follow-up study
-
Differential Impacts of Admission LDL-Cholesterol on Early Vascular Outcomes by Ischemic Stroke Subtypes J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-26 Joon-Tae Kim, Ji Sung Lee, Hyunsoo Kim, Beom Joon Kim, Jihoon Kang, Keon-Joo Lee, Jong-Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Jae-Kwan Cha, Dae-Hyun Kim, Tai Hwan Park, Kyung Bok Lee, Jun Lee, Keun-Sik Hong, Yong-Jin Cho, Hong-Kyun Park, Byung-Chul Lee, Kyung-Ho Yu, Hee-Joon Bae
Background : Because ischemic stroke is heterogeneous, the associations between LDL-cholesterol levels and early vascular outcomes might be different according to the stroke subtype in acute ischemic stroke patients. Methods : This study was an analysis of a prospective, multicenter, stroke registry. Acute ischemic stroke patients previously not treated with statins were included. Admission LDL-cholesterol
-
Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-23 Martin Satny, Veronika Todorovova, Tereza Altschmiedova, Jaroslav A. Hubacek, Lucie Dlouha, Vera Lanska, Vladimir Soska, Ondrej Kyselak, Tomas Freiberger, Martin bobak, Michal Vrablik
Background Familial dysbetalipoproteinemia (FD) is an autosomal recessive (rarely dominant) inherited disorder that is almost exclusively associated with the apolipoprotein E gene (APOE) variability. Nonetheless, only a small proportion of APOE2/E2 subjects develop the phenotype for mixed dyslipidemia; the context of other trigger metabolic or genetic factors remains unknown. Methods One hundred and
-
Effectiveness of the triglyceride-glucose index and triglyceride-glucose-related indices in predicting cardiovascular disease in middle-aged and older adults: A prospective cohort study J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-19 Hye-Min Park, Taehwa Han, Seok-Jae Heo, Yu-Jin Kwon
Backgrounds Cardiovascular disease (CVD) risk assessment is a crucial component of public health. We aimed to determine the predictive value of the TyG index and TyG-related indices for new-onset CVD. Methods This prospective study included 7,808 participants aged 40-69 years from the Ansung-Ansan cohort database. Our analysis was stratified by diabetes status. The hazard ratio (HR) with a 95% confidence
-
Advancements in Non-Invasive Imaging of Atherosclerosis: Future Perspectives J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-19 Joana Guimarães, José de Almeida, Paulo Lázaro Mendes, Maria João Ferreira, Lino Gonçalves
Atherosclerosis is a chronic inflammatory disease characterized by the buildup of plaques in arterial walls, leading to cardiovascular diseases and high morbidity and mortality rates worldwide. Non-invasive imaging techniques play a crucial role in evaluating patients with suspected or established atherosclerosis. However, there is a growing body of evidence suggesting the need to visualize the underlying
-
Cascade Testing of Children and Adolescents for Elevated Lp(a) in Pedigrees with Familial Hypercholesterolaemia J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-17 Wann Jia Loh, Jing Pang, Anindita Chakraborty, Natalie C. Ward, Dick C. Chan, Amanda J. Hooper, Damon A. Bell, John R. Burnett, Andrew C. Martin, Gerald F. Watts
Elevated plasma lipoprotein(a) [Lp(a)] is a common, inherited condition independently causing cardiovascular disease. Recent expert recommendations suggest opportunistically testing for elevated Lp(a) during cascade testing for familial hypercholesterolaemia (FH). We investigated the effectiveness of detecting elevated Lp(a) in 103 children and adolescents who were first-degree relatives of 66 adult
-
Comparison of Virtual vs Face-to-face Medical Nutrition Therapy in Patients with Hyperlipidemia J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-17 Shannon Zoulek, Jackson Shriver, Navkiranjot Kaur, Beverly Kuznicki, Eric J. Brandt
Since the COVID-19 pandemic, utilization of telemedicine visits has increased. The outcomes of virtual compared to face-to-face (F2F) visits for treating hyperlipidemia is uncharacterized. This observational study compared pre- to post-visit change in lipid markers between 41 virtual and 151 F2F visits with a registered dietitian nutritionist at the University of Michigan Preventive Cardiology program
-
Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-11 Anurag Mehta, Terence B. Lee, Pamela Alebna, Gowtham R. Grandhi, Dave L. Dixon, Fadi N. Salloum, Arun J. Sanyal, Mohammad S. Siddiqui
Nonalcoholic fatty liver disease (NAFLD) is associated with atherogenic dyslipidemia and an increased risk of cardiovascular events. Previous studies have suggested an inverse relationship between NAFLD severity and lipoprotein(a) [Lp(a)] level, but contemporary data from the U.S. are lacking. Lp(a), lipid profile, apolipoproteins, and nuclear magnetic resonance-based lipoprotein particle concentrations
-
Characteristics and prognosis of patients with elevated triglycerides in acute myocardial infarction: observational data from a large database over a 17-year period J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-10 Marianne ZELLER, Frédéric CHAGUE, Maud MAZA, Florence BICHAT, Yves COTTIN, Michel FARNIER
From a large regional registry, we aimed to address the characteristics and prognosis of patients with elevated triglycerides (TG) among patients hospitalized for an acute myocardial infarction (MI). From the multicenter database of the RICO survey, all consecutive patients hospitalized for an acute MI (2001-2017) and alive at discharge were included. Among the 10,667 patients included, 17.7% had elevated
-
Molecular genetic testing and measurement of levels of GPIHBP1 autoantibodies in patients with severe hypertriglyceridemia: The importance of identifying the underlying cause of hypertriglyceridemia. J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-07 Thea Bismo Strøm, Anders Aune Tveita, Martin Prøven Bogsrud, Trond P. Leren
Background Severe hypertriglyceridemia can be caused by pathogenic variants in genes encoding proteins involved in the metabolism of triglyceride-rich lipoproteins. A key protein in this respect is lipoprotein lipase (LPL) which hydrolyzes triglycerides in these lipoproteins. Another important protein is glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) which
-
A systematic review of cost-effectiveness analysis of different screening strategies for familial hypercholesterolemia J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-07 Rui Meng, Qiran Wei, Jiting Zhou, Baoming Zhang, Chao Li, Mingwang Shen
AIMS Diagnosis rate of familial hypercholesterolemia (FH) remained less than 10 % globally and the economic evaluation results of different FH screening strategies varied. This study aimed to systematically review the methodology and results of cost effectiveness analysis (CEA) of FH screening, which will provide evidence support for health-related decision-making. METHODS The Medline/PubMed, Embase
-
Carotenoids in familial hypobetalipoproteinemia disorders: malabsorption in Caco2 cell models and severe deficiency in patients. J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-11-04 Claire Bordat, Charlotte Cuerq, Charlotte Halimi, Donato Vairo, Emilie Blond, Liora Restier, Pierre Poinsot, Rémi Duclaux-Loras, Noël Peretti, Emmanuelle Reboul
Background Familial hypobetalipoproteinemias (FHBL) are rare genetic diseases characterized by lipid malabsorption. We focused on abetalipoproteinemia (FHBL-SD1) and chylomicron retention disease (FHBL-SD3), caused by mutations in MTTP and SAR1B genes, respectively. Treatments include a low-fat diet and high-dose liposoluble vitamin supplementations. However, patients are not supplemented in carotenoids
-
Safety of Bempedoic Acid in Patients at High Cardiovascular Risk and with Statin Intolerance J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-31 Harold E. Bays, LeAnne T. Bloedon, Grace Lin, Heather Powell, Michael J. Louie, Stephen J. Nicholls, A. Michael Lincoff, Steven Nissen
-
Effect of PCSK9 Inhibition on Plasma Levels of Small Dense Low Density Lipoprotein-Cholesterol and 7-Ketocholesterol: Effect of PCSK9 Inhibition on sdLDL-C and 7-Ketocholesterol J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-22 Tahir Mahmood, Joshua R. Miles, Jessica Minnier, Hagai Tavori, Andrea E. DeBarber, Sergio Fazio, Michael D. Shapiro
Background : Oxidized forms of cholesterol (oxysterols) are implicated in atherogenesis and can accumulate in the body via direct absorption from food or through oxidative reactions of endogenous cholesterol, inducing the formation of LDL particles loaded with oxidized cholesterol. It remains unknown whether drastic reductions in LDL-cholesterol (LDL-C) are associated with changes in circulating oxysterols
-
Comparison of the burden of familial hypercholesterolemia between two cohorts of French Canadians hospitalized 25 years apart for coronary heart disease J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-20 Alex Lauzière, Diane Brisson, Gérald Tremblay, Sophie Bédard, Etienne Khoury, Daniel Gaudet
Background : Familial hypercholesterolemia (FH) is associated with lifelong elevated plasma concentrations of low-density lipoprotein cholesterol (LDL-C) and high risk of premature coronary heart disease (CHD). Clinical recommendations and treatments have emerged to facilitate the management of FH patients. Their impact on the burden of FH is however not well documented. Objective : To compare the
-
Sex differences in the perception of cardiovascular risk in familial hypercholesterolemia J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-19 Balaqis Alshibani, Iulia Iatan, Amanda Guerin, Isabelle Ruel, Lubomira Cermakova, Agnihotram V. Ramanakumar, Louise Pilote, Thais Coutinho, Liam R. Brunham, Jacques Genest
-
Evaluation of Apolipoprotein A5 Variants: A Cohort of Patients with Severe Hypertriglyceridemia from Turkiye J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-12 B Cakmak, S Yeral, B Ozcan, E Pariltay, S Ozgul, IY Simsir, RA Hegele
Background This study aims to show the clinical and biochemical features in patients with severe hypertriglyceridemia (HTG) associated with rare variants in the apolipoprotein A-V (APOA5) gene. Materials and Methods Demographics, blood lipid levels, body mass index (BMI) and APOA5 mutation subtypes were collected from the endocrinology clinic registry and analyzed for a retrospective cohort study of
-
Association between Remnant Cholesterol and Incident Atherosclerotic Cardiovascular Disease, Heart Failure, and Atrial Fibrillation J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-14 Hayato Tada, Hidehiro Kaneko, Yuta Suzuki, Akira Okada, Norifumi Takeda, Katsuhito Fujiu, Hiroyuki Morita, Junya Ako, Koichi Node, Yasuaki Takeji, Masayuki Takamura, Hideo Yasunaga, Issei Komuro
Background It remains unclear if remnant cholesterol is associated with atherosclerotic cardiovascular disease (ASCVD) (myocardial infarction, angina pectoris and stroke), heart failure (HF), and atrial fibrillation (AF) under primary prevention settings. Objective We aimed to clarify this issue among a general population without a history of ASCVD, HF or AF. Methods Analyses were conducted with a
-
Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipidology, Volume 17, Issue 3, May–June 2023, Pages 342–355] J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-13 Joseph L. Witztum, Daniel Gaudet, Marcello Arca, Alan Jones, Handrean Soran, Ioanna Gouni-Berthold, Erik S.G. Stroes, Veronica J. Alexander, Richard Jones, Lynnetta Watts, Shuting Xia, Sotirios Tsimikas
Abstract not available
-
Chanarin-Dorfman Syndrome diagnosed at the stage of liver transplantation: A rare lipid storage disease J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-12 Esra Durmazer, Meryem Demir, Huseyin Onay, Fulya Gunsar
Chanarin-Dorfman Syndrome (CDS); is a rare lipid storage disease with ichthyosis, hepatomegaly, myopathy, neuropathy, deafness, and ocular findings. Here, we aim to present a elderly CDS case with highlightening the new endocrinological findings. A 66-year-old male patient with cirrhosis hospitalized for liver transplantation. We suspected Chanarin-Dorfman Syndrome with ichthyosis, fatty liver, and
-
-
Impact of the Spanish consensus for improving lipid control on patients admitted for an acute coronary syndrome J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-05 Carlos Escobar, Vivencio Barrios, Angel Cequier, Juan Cosin-Sales, Jose Seijas, Juan José Gómez Doblas, Vicente Arrarte, Jose Tuñon, Maciej Banach
-
-
From the Editors: Inhibition of cholesteryl ester transfer protein (CETP): Still a promising therapeutic strategy? J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-03 P. Barton Duell, Kevin C. Maki
Abstract not available
-
-
Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-04 Gregory A. Panza, Olivia Blazek, Joseph Tortora, Stephanie Saucier, Antonio B. Fernandez
Introduction Lipoprotein(a) [Lp(a)] is a genetically determined independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease. Despite recommendations from professional societies in the cardiovascular field, the awareness of elevated Lp(a) as a risk factor and screening for Lp(a) are suspected to be low. Methods We conducted a retrospective, observational
-
NLA/ASPC response to the USPSTF recommendation statement on screening lipid panel in children and adolescents J. Clin. Lipidol. (IF 4.4) Pub Date : 2023-10-04 Anne Carol Goldberg, Daniel Soffer, Christie Ballantyne, Martha Gulati, Michael Shapiro
Abstract not available